ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and Sino Biopharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaSino Biopharmaceutical
studies on the registry4,197471
open to participants now298163
phase 3 studies under way20046
reach primary completion within a year16857
programswith a study of their own in two years119+5 named only97+19 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaSino Biopharmaceutical
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Sino Biopharmaceutical: 37 of its 97 programs at phase 1

  1. TQF3250phase 1
  2. TQB2101phase 1
  3. 1200mg of tqb2928 injectionphase 1
  4. Anecatibin Fumarate Capsulesphase 1
  5. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1

and 32 more — sign in to see them all

38%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Sino Biopharmaceutical: 31 of its 97 programs at phase 2

  1. JAK2 Inhibitor TQ05105phase 2
  2. TQB2922phase 2
  3. TRD205phase 2
  4. BTK Inhibitor TQB3702phase 2
  5. TQB6411phase 2

and 26 more — sign in to see them all

32%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Sino Biopharmaceutical: 26 of its 97 programs at phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. NTQ5082phase 3
  5. culmerciclibphase 3

and 21 more — sign in to see them all

27%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Sino Biopharmaceutical: 3 of its 97 programs at approved, new studies

  1. catequentinib hydrochlorideapproved, new study
  2. Adalimumabapproved, new study
  3. TyboWe® Adalimumab Injectionapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Sino Biopharmaceutical37 readouts · 10 phase 3

Sino Biopharmaceutical, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868phase 3 · Nov 0 · NCT06767813
  2. NTQ5082phase 3 · Nov 0 · NCT07177859
  3. TQB2252phase 1 · Nov 0 · NCT06649656
  4. TQH2722phase 3 · Nov 0 · NCT07398859

Sino Biopharmaceutical, Dec ’26: 14 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-HER2 Bispecific Antibody TQB2930phase 3 · Dec 0 · NCT06202261
  2. BET Inhibitor TQB3617phase 2 · Dec 0 · NCT06122831
  3. BTK Inhibitor TQB3702phase 2 · Dec 0 · NCT06859931
  4. catequentinib hydrochlorideapproved, new study · Dec 0 · NCT04344158
  5. culmerciclibphase 3 · Dec 0 · NCT05780567

and 9 more — sign in to see them all

Sino Biopharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3 · Jan 0 · NCT06561607
  2. vilzemetkibphase 3 · Jan 0 · NCT06860971

Sino Biopharmaceutical, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB6411phase 2 · Feb 0 · NCT07367516
  2. TQC3721phase 3 · Feb 0 · NCT07464587

Sino Biopharmaceutical, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anecatibin Fumarate Capsulesphase 1 · Mar 0 · NCT07538973
  2. TQB3473phase 3 · Mar 0 · NCT06900920
  3. TQC2938phase 2 · Mar 17 · NCT06789289

Sino Biopharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion

  1. NTQ6179phase 1 · Apr 0 · NCT07909837
  2. TQB3201phase 2 · Apr 0 · NCT07172126

Sino Biopharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. NTB003phase 2 · May 31 · NCT07462130
·

Sino Biopharmaceutical, Jul ’27: 2 programs whose next study reaches primary completion

  1. TQD3524phase 2 · Jul 0 · NCT07512596
  2. TQH3906phase 3 · Jul 0 · NCT06754891

Sino Biopharmaceutical, Aug ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB2916phase 2 · Aug 0 · NCT06962267
  2. TQB6426phase 1 · Aug 0 · NCT07730190
  3. trifluridine tipiracil drug combinationphase 3 · Aug 0 · NCT07483684
  4. LM-168phase 2 · Aug 1 · NCT06868199
  5. KYLO-0603phase 2 · Aug 15 · NCT07878091
·

Sino Biopharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3 · Oct 0 · NCT07179679
  2. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1 · Oct 30 · NCT04740424
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Sino Biopharmaceutical

New programs 3

  • NTQ6179phase 1 · first study · Oct 20 · Acromegaly
  • KYLO-0603phase 2 · first study · Sep 24 · Non-alcoholic Fatty Liver Disease
  • TQF6422phase 1 · first study · Aug 26 · Obesity

Reached a new phase 1

  • TQA3605phase 3 · Aug 28 · Hepatitis B, Chronic

Study stopped 0

None

Primary completion later 4

Where they overlap

Conditions where at least two of them have programs: 46 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaSino Biopharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Sino Biopharmaceutical in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. vilzemetkibphase 3
  5. FHND-9041phase 3

and 5 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Prostatic Neoplasmsboth · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Sino Biopharmaceutical in Prostatic Neoplasms: 2 programs

  1. TQB3201phase 2
  2. Androgen Receptor Antagonist TQB3720phase 1

Their studies: Sino Biopharmaceutical’s studies of Prostatic Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Sino Biopharmaceutical in Pulmonary Disease, Chronic Obstructive: 6 programs

  1. TQC2731phase 3
  2. TQC3721phase 3
  3. TQC2938phase 2
  4. TQC3927phase 2
  5. TQC3302phase 1

and 1 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Pulmonary Disease, Chronic Obstructive in search

Asthmaboth · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Sino Biopharmaceutical in Asthma: 2 programs

  1. TQC2731phase 3
  2. TQC2938phase 2

Their studies: Sino Biopharmaceutical’s studies of Asthma in search

Stomach Neoplasmsboth · compare here

Sino Biopharmaceutical in Stomach Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. tislelizumabphase 2

Their studies: Sino Biopharmaceutical’s studies of Stomach Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Sino Biopharmaceutical in Carcinoma, Hepatocellular: 3 programs

  1. penpulimabphase 3
  2. tislelizumabphase 2
  3. catequentinib hydrochlorideapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Hepatocellular in search

Neoplasmsboth · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Sino Biopharmaceutical in Neoplasms: 2 programs

  1. LM-364phase 2
  2. LM-350phase 2

Their studies: Sino Biopharmaceutical’s studies of Neoplasms in search

Lymphoma, Follicularboth · compare here

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Sino Biopharmaceutical in Lymphoma, Follicular: 2 programs

  1. TQB2825phase 3
  2. JAK2 Inhibitor TQ05105phase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Follicular in search

Multiple Myelomaboth · compare here

Sino Biopharmaceutical in Multiple Myeloma: 3 programs

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3
  2. FHND6091phase 1
  3. TQB2029phase 1

Their studies: Sino Biopharmaceutical’s studies of Multiple Myeloma in search

Obesityboth · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Sino Biopharmaceutical in Obesity: 3 programs

  1. Semaglutidephase 3
  2. TQF3250phase 1
  3. TQF6422phase 1

Their studies: Sino Biopharmaceutical’s studies of Obesity in search

Colorectal Neoplasmsboth · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Diabetes Mellitus, Type 2both · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Sino Biopharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. Semaglutidephase 3

Their studies: Sino Biopharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Endometrial Neoplasmsboth · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Sino Biopharmaceutical in Endometrial Neoplasms: 2 programs

  1. benmelstobartphase 3
  2. catequentinib hydrochlorideapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Endometrial Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Sino Biopharmaceutical in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. Bcl-2 Inhibitor TQB3909phase 3

Their studies: Sino Biopharmaceutical’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Pancreatic Neoplasmsboth · compare here

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Hematologic Neoplasmsboth · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Sino Biopharmaceutical in Hematologic Neoplasms: 4 programs

  1. Bcl-2 Inhibitor TQB3909phase 3
  2. TQB2825phase 3
  3. TQB3473phase 3
  4. BTK Inhibitor TQB3702phase 2

Their studies: Sino Biopharmaceutical’s studies of Hematologic Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

Sino Biopharmaceutical in Lupus Erythematosus, Systemic: 2 programs

  1. TQH3906phase 3
  2. BTK Inhibitor TQB3702phase 2

Their studies: Sino Biopharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Triple Negative Breast Neoplasmsboth · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Sino Biopharmaceutical in Triple Negative Breast Neoplasms: 1 program

  1. benmelstobartphase 3

Their studies: Sino Biopharmaceutical’s studies of Triple Negative Breast Neoplasms in search

Lymphoma, B-Cellboth · compare here

Sino Biopharmaceutical in Lymphoma, B-Cell: 1 program

  1. TQB3702 tablets+Chemotherapy regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, B-Cell in search

Neoplasm Metastasisboth · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Sino Biopharmaceutical in Neoplasm Metastasis: 1 program

  1. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1

Their studies: Sino Biopharmaceutical’s studies of Neoplasm Metastasis in search

Non-alcoholic Fatty Liver Diseaseboth · compare here

AstraZeneca in Non-alcoholic Fatty Liver Disease: 1 program

  1. AZD9550phase 2

Their studies: AstraZeneca’s studies of Non-alcoholic Fatty Liver Disease in search

Sino Biopharmaceutical in Non-alcoholic Fatty Liver Disease: 3 programs

  1. Semaglutidephase 3
  2. KYLO-0603phase 2
  3. lanifibranorphase 1

Their studies: Sino Biopharmaceutical’s studies of Non-alcoholic Fatty Liver Disease in search

Small Cell Lung Carcinomaboth · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Sino Biopharmaceutical in Small Cell Lung Carcinoma: 2 programs

  1. benmelstobartphase 3
  2. trifluridine tipiracil drug combinationphase 3

Their studies: Sino Biopharmaceutical’s studies of Small Cell Lung Carcinoma in search

Amyloidosisboth · compare here

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

Sino Biopharmaceutical in Amyloidosis: 1 program

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3

Their studies: Sino Biopharmaceutical’s studies of Amyloidosis in search

Arthritis, Rheumatoidboth · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Sino Biopharmaceutical in Arthritis, Rheumatoid: 1 program

  1. Adalimumabapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Arthritis, Rheumatoid in search

Cardiovascular Diseasesboth · compare here

AstraZeneca in Cardiovascular Diseases: 2 programs

  1. laroprovstatphase 3
  2. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Cardiovascular Diseases in search

Sino Biopharmaceutical in Cardiovascular Diseases: 1 program

  1. KYLO-11no phase

Their studies: Sino Biopharmaceutical’s studies of Cardiovascular Diseases in search

Crohn Diseaseboth · compare here

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Sino Biopharmaceutical in Crohn Disease: 2 programs

  1. Adalimumabapproved, new study
  2. TyboWe® Adalimumab Injectionapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Crohn Disease in search

Hemoglobinuria, Paroxysmalboth · compare here

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

Sino Biopharmaceutical in Hemoglobinuria, Paroxysmal: 1 program

  1. NTQ5082phase 3

Their studies: Sino Biopharmaceutical’s studies of Hemoglobinuria, Paroxysmal in search

Lung Neoplasmsboth · compare here

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Sino Biopharmaceutical in Lung Neoplasms: 2 programs

  1. TQB6411phase 2
  2. Anecatibin Fumarate Capsulesphase 1

Their studies: Sino Biopharmaceutical’s studies of Lung Neoplasms in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Sino Biopharmaceutical in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. TQB2825phase 3
  2. gemcitabine-oxaliplatin regimenphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Lymphoma, Mantle-Cellboth · compare here

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

Sino Biopharmaceutical in Lymphoma, Mantle-Cell: 1 program

  1. 400mg of TQB3909 tabletsphase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Mantle-Cell in search

Nasal Polypsboth · compare here

AstraZeneca in Nasal Polyps: 2 programs

  1. tezepelumabapproved, new study
  2. benralizumabapproved, new study

Their studies: AstraZeneca’s studies of Nasal Polyps in search

Sino Biopharmaceutical in Nasal Polyps: 1 program

  1. TQC2731phase 3

Their studies: Sino Biopharmaceutical’s studies of Nasal Polyps in search

Ovarian Neoplasmsboth · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Sino Biopharmaceutical in Ovarian Neoplasms: 1 program

  1. vilzemetkibphase 3

Their studies: Sino Biopharmaceutical’s studies of Ovarian Neoplasms in search

Acromegalyboth · compare here

AstraZeneca in Acromegaly: 1 program

  1. ALXN2420phase 2

Their studies: AstraZeneca’s studies of Acromegaly in search

Sino Biopharmaceutical in Acromegaly: 1 program

  1. NTQ6179phase 1

Their studies: Sino Biopharmaceutical’s studies of Acromegaly in search

Biliary Tract Neoplasmsboth · compare here

AstraZeneca in Biliary Tract Neoplasms: 1 program

  1. rilvegostomigphase 3

Their studies: AstraZeneca’s studies of Biliary Tract Neoplasms in search

Sino Biopharmaceutical in Biliary Tract Neoplasms: 1 program

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3

Their studies: Sino Biopharmaceutical’s studies of Biliary Tract Neoplasms in search

Colitis, Ulcerativeboth · compare here

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Sino Biopharmaceutical in Colitis, Ulcerative: 1 program

  1. Adalimumabapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Colitis, Ulcerative in search

Dermatitis, Atopicboth · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Sino Biopharmaceutical in Dermatitis, Atopic: 1 program

  1. TQH2722phase 3

Their studies: Sino Biopharmaceutical’s studies of Dermatitis, Atopic in search

Diabetes Mellitusboth · compare here

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

Sino Biopharmaceutical in Diabetes Mellitus: 1 program

  1. Semaglutidephase 3

Their studies: Sino Biopharmaceutical’s studies of Diabetes Mellitus in search

Glomerulonephritis, IGAboth · compare here

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

Sino Biopharmaceutical in Glomerulonephritis, IGA: 1 program

  1. NTQ5082phase 3

Their studies: Sino Biopharmaceutical’s studies of Glomerulonephritis, IGA in search

Head and Neck Neoplasmsboth · compare here

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Sino Biopharmaceutical in Head and Neck Neoplasms: 1 program

  1. TQB2922phase 2

Their studies: Sino Biopharmaceutical’s studies of Head and Neck Neoplasms in search

Idiopathic Pulmonary Fibrosisboth · compare here

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Sino Biopharmaceutical in Idiopathic Pulmonary Fibrosis: 1 program

  1. TDI01phase 3

Their studies: Sino Biopharmaceutical’s studies of Idiopathic Pulmonary Fibrosis in search

Kidney Diseasesboth · compare here

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

Sino Biopharmaceutical in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: Sino Biopharmaceutical’s studies of Kidney Diseases in search

Liposarcomaboth · compare here

AstraZeneca in Liposarcoma: 1 program

  1. atirmociclibphase 2

Their studies: AstraZeneca’s studies of Liposarcoma in search

Sino Biopharmaceutical in Liposarcoma: 1 program

  1. culmerciclibphase 3

Their studies: Sino Biopharmaceutical’s studies of Liposarcoma in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

AstraZeneca in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibphase 2

Their studies: AstraZeneca’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Sino Biopharmaceutical in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. TQB3473phase 3

Their studies: Sino Biopharmaceutical’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Rhinosinusitisboth · compare here

AstraZeneca in Rhinosinusitis: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Rhinosinusitis in search

Sino Biopharmaceutical in Rhinosinusitis: 1 program

  1. TQH2722phase 3

Their studies: Sino Biopharmaceutical’s studies of Rhinosinusitis in search

Uterine Cervical Neoplasmsboth · compare here

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaSino Biopharmaceutical
CD3Esurovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934, TQB2825, TQB2029
PDCD1rilvegostomig, volrustomigAnti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868, TQB2252, penpulimabrule, tislelizumabrule
BTKacalabrutinibrule, pirtobrutinibruleBTK Inhibitor TQB3702, TQB3702 tablets+Chemotherapy regimen, TQB3019
EGFRosimertinibruleFHND-9041, TQB2922, TQB6411, TQB3002
CLDN18sonesitatug vedotin, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360ruletecotabart vedotin
ERBB2trastuzumab deruxtecanruleAnti-HER2 Bispecific Antibody TQB2930, Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102, kg of tqb2102 for injection
ARAndrogen Receptor Degrader AZD9750ruleTQB3201, Androgen Receptor Antagonist TQB3720
CD274durvalumabruleAnti-CD137/PD-L1 Bispecific Antibody FS222, benmelstobartrule
CTLA4volrustomig, tremelimumabruleLM-168
GLP1RAZD9550TQF3250, Semaglutiderule
MS4A1Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, CT204V-CD19 × CD20ruleTQB2825
PARP1palacaparib, saruparibruleTQB3122
TNFRSF17Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Allogeneic Anti-BCMA CAR T-cells AZD4045Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934
ATMAZD1390TQB3117
ATRceralasertibruleTCC1727
CDK4atirmociclibculmerciclib
GPC3Anti-GPC3 T Cell-engaging Antibody AZD9793TQB6426rule
GPRC5Dvemzatatug vedotinTQB2029
NR3C1BudesonideruleTQC3302
TSLPtezepelumabruleTQC2731
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Sino Biopharmaceutical 70 of 97 programs (37 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Sino Biopharmaceutical: 19).